Search results
Results from the WOW.Com Content Network
A 2014 Canadian study calculated the cost per life-year-gained with treatment as CAN$4.62 million (US$4,571,564) and cost per quality-adjusted-life-year as CAN$2.13 million (US$2,112,398)."The incremental cost per life year and per QALY gained is CAN$4.62 million and CAN$2.13 million, respectively.
According to data from the Drug Policy Alliance, the United States government spends $39 billion each year on the war on d***s. Cumulatively, it amounts to $1 trillion since 1971. However, recent ...
Supporters of direct-to-consumer advertising argue that advertisements increase competition which leads to lower prescription drug prices and new development, citing, for instance, that between 1997 and 2001, spending on research and development in the U.S. increased 59% while spending on promoting drugs directly to patients increased 145%.
A tenth, approved in November, is predicted to run about $3.8 million, just shy of the most expensive, also approved last year, which costs $4.25 million a dose. “Drug companies charge whatever ...
ALTO-100, previously known as NSI-189 (NeuralStem Inc. 189), [3] is a drug described as a hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator which is under development for the treatment of major depressive disorder (MDD), bipolar depression, and post-traumatic stress disorder (PTSD).
In response, the Center for Medicare and Medicaid Innovation proposed a handful of potential projects, one of which would have invited Medicare prescription drug plans to voluntarily offer a ...
In one case, product hopping of the multiple sclerosis drug glatiramer acetate (Copaxone) led to a cost to consumers of $4.3 to 6.5 billion dollars over two and a half years, before the new patent was invalidated by the courts. [13] Another example was the Alzheimer's drug memantine (Namenda). [12]
Some PROTACs have been shown to be more selective than their inhibitor analogues, reducing off-target effects. [20] PROTACs have the ability to target previously undruggable proteins, as they do not need to target catalytic pockets. [20] This also helps prevent mutation-driven drug resistance often found with enzymatic inhibitors.